KUKazım Uygun

Kazım Uygun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazım Uygun has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinicopathological features of breast cancer in women ≤35 years: A retrospective single-center study

    by Fatma Geçgel, Ali Kaan Güren, Devrim Çabuk, Kazım Uygun

    Objective: Although breast cancer (BC) predominantly affects women aged ≥ 50 years, its incidence among younger women is increasing. Younger patients often present with aggressive biological features. This study aimed to compare the clinicopathological characteristics and survival outcomes between BC patients aged ≤35 years and those >35 years.Materials and Methods: We retrospectively reviewed the data of 933 BC patients treated at Kocaeli University between 2006 and 2011. Patients were stratified by age (≤35 vs >35y). Demographics, tumor characteristics (TNM stage, grade, receptor status, lymph node involvement), and overall survival were analyzed.Results: Median age was 52 years (24-89). Of the total cohort, 6% were ≤ 35 years and 46% were premenopausal. Younger patients more frequently had T3 tumors (23% vs. 10%; p=0.049). However, no significant differences were observed regarding nodal status, histological grade, receptor expression, or survival (5-years OS 72% vs.74%, p=0.629). Each one-year increase in age was associated with an increased mortality risk (OR 1.04; 95% Cl, 1.02-1.06). Conclusion: While younger BC patients in our cohort presented more frequently with advanced T stage, their pathological features and survival rates were largely comparable across age groups. These results highlight importance of individualized management in young women and underscore the need for prospective studies to define age-specific prognostic and therapeutic implications.

  • Open Access

    Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma

    by İlkay Çıtakkul, Hayati Arvas, Mert Karaoğlan, Bahadır Köylü, Nazan Demir, Gözde Balkaya Aykut, Elif Şahin, Mesut Yılmaz, Zuhat Urakçı, Duygu Bayır Garbioğlu, et al.

    Second-line chemotherapy is widely used in metastatic urothelial carcinoma after progression on first-line platinum-based therapy, but its independent contribution to survival, as opposed to selection of healthier patients, remains unclear. In this multicenter retrospective cohort of 142 patients treated with first-line platinum-based chemotherapy across seven Turkish centers, overall survival (OS) from first-line progression was compared between patients who received second-line chemotherapy (n = 80) and those who did not (n = 62), using multivariable Cox regression, inverse probability of treatment weighting (IPTW), propensity-score matching, landmark analysis, and a time-dependent Cox model. Median OS was 7.4 versus 4.7 months (log-rank p = 0.064). Second-line chemotherapy was independently associated with improved OS on multivariable analysis (adjusted hazard ratio [aHR] 0.620; 95% confidence interval [CI] 0.423–0.907; p = 0.014); Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 (aHR 3.881; p = 0.001) and lower albumin (aHR 0.671; p = 0.018) were also independent predictors. The association remained significant after IPTW (HR 0.648; p = 0.025) and after a time-dependent Cox model (HR 0.632; p = 0.019), and was unchanged in ECOG-restricted and Bellmunt-adjusted analyses (p = 0.008, p = 0.029); it narrowly missed significance after propensity-score matching (HR 0.645; p = 0.051) and did not reach significance in the 3-month landmark analysis (HR 0.743; p = 0.180). Power was limited (~49%). In a time-dependent Cox model—the analysis least susceptible to immortal-time bias, as it retains the full cohort and classifies pre-treatment person-time as unexposed—second-line chemotherapy remained independently associated with improved OS (HR 0.632; p = 0.019), closely consistent with the primary multivariable estimate. The conventional Cox, IPTW, and propensity-score-matched analyses, which treat second-line receipt as a baseline exposure, were directionally concordant but share a common time-related bias and are therefore not independent confirmations. ECOG performance status was a consistent predictor throughout.

  • Prognostic value of the PLACE score in a Turkish cohort of metastatic pleural mesothelioma

    by İlKay Çıtakkul, Yasemin Bakkal Temi, Hilmi Zengin, Mertcan Önen, Ece Baydar, Umut Kefeli, Devrim Çabuk, Kazım Uygun

    Aims: Pleural mesothelioma is an aggressive malignancy with poor prognosis and limited therapeutic options. Reliable prognostic models are essential for risk stratification and clinical decision-making. The recently developed PLACE score has shown promising results in Chinese populations; however, its generalizability remains uncertain. This study aimed to externally validate the PLACE prognostic score in a Turkish cohort of patients with metastatic epithelioid pleural mesothelioma. Methods: This retrospective cohort study included patients diagnosed with metastatic epithelioid pleural mesothelioma at a single tertiary center between January 2016 and September 2025. Clinical and laboratory data at diagnosis were collected, and the PLACE score was calculated for each patient. Overall survival (OS) was analyzed using the Kaplan–Meier method, and differences between risk groups were compared using the log-rank test. Cox proportional hazards regression analysis was performed to evaluate the association between prognostic variables and survival. The discriminative ability of the PLACE score was assessed using receiver operating characteristic (ROC) curve analysis. Results: A total of 48 patients were included, with a median age of 66 years. According to the PLACE score, 33.3% of patients were classified as low-risk and 66.7% as high-risk. The median overall survival was 21.06 months. Patients in the low-risk group had significantly longer survival compared to the high-risk group (37.98 vs. 15.6 months, p=0.033). The PLACE score demonstrated limited discriminative ability, with an area under the curve (AUC) of 0.617 (95% CI: 0.413–0.821). In Cox regression analysis, high-risk patients had a significantly increased risk of mortality (HR: 2.28, 95% CI: 1.04–4.95, p=0.037). In multivariable analysis, the PLACE risk group remained an independent predictor of overall survival. Conclusion: The PLACE score retains prognostic significance in Turkish patients with metastatic pleural mesothelioma but demonstrates reduced discriminative performance compared to the original study. These findings emphasize the need for external validation and potential population-specific recalibration of prognostic models.

  • Open Access

    EASIX Score as an Independent Prognostic Marker in De Novo Metastatic Pancreatic Cancer

    by İlkay Çıtakkul, Yasemin Bakkal Temi, Zehra Aytin, Ece Baydar, Umut Kefeli, Devrim Çabuk, Kazım Uygun

    Background and Objectives: Metastatic pancreatic ductal adenocarcinoma carries a dismal prognosis and there is an unmet need for simple, widely available prognostic biomarkers to guide risk stratification and treatment planning. This study aimed to evaluate whether baseline EASIX score, calculated from routine laboratory parameters (LDH, creatinine, platelet count), predicts overall survival (OS) in patients with de novo metastatic pancreatic cancer. Materials and Methods: We performed a retrospective cohort study at a single tertiary center (Medical Oncology Department, Kocaeli University Faculty of Medicine) including 332 patients diagnosed with de novo metastatic pancreatic ductal adenocarcinoma between January 2019 and October 2025. Baseline EASIX was calculated using LDH, creatinine, and platelet count. Statistical analyses included ROC analysis with Youden index to determine exploratory cut-off, Kaplan–Meier survival estimation with log-rank test, and univariate and multivariate Cox proportional hazards regression to identify independent prognostic factors. The primary endpoint was OS, defined as time from initiation of first-line therapy to death from any cause. Results: A total of 332 patients were included. Median OS was 8.0 months overall. Patients with high EASIX (>2.505) had significantly shorter median OS compared with low EASIX patients (8.4 vs. 27.6 months, p < 0.001). ROC analysis was considered exploratory for overall survival; therefore, an additional fixed-time (12-month mortality) ROC analysis was performed to provide a discrimination estimate accounting for censoring. The AUC for EASIX was 0.887 (95% CI: 0.816–0.958), and the exploratory cut-off determined was 2.505 (sensitivity 96.95%, specificity 72.97%). In multivariate Cox regression, high EASIX remained an independent predictor of worse OS (HR 4.124; 95% CI: 2.011–8.457; p < 0.001) after adjustment for relevant covariates. Conclusions: Baseline EASIX score is an independent prognostic marker for overall survival in de novo metastatic pancreatic cancer, based on routine laboratory tests, and may facilitate exploratory risk stratification. Prospective validation in independent cohorts is warranted before clinical implementation.


  • Real-World Outcomes of Irinotecan–Bevacizumab Therapy in Recurrent Brain Tumors: A Retrospective Cohort Study

    by Mustafa Seyyar, Pervin Can Şancı, Ali Kalem, Burak Mete, Tolga Köşeci, Anıl Karakayalı, Mehmet Uzun, Teoman Sakalar, Yasemin Bakkal Temi, Melike Yazıcı, et al.

    Aim: Although the irinotecan–bevacizumab (IB) combination is a frequently used treatment option in recurrent brain tumors, clinical benefit shows heterogeneity among patient subgroups. This study aimed to evaluate clinical and prognostic factors associated with early-stage mortality and overall survival (OS) in patients receiving IB treatment. Material and Methods: Seventy-eight brain tumor patients who received IB treatment between 2015 and 2023 were retrospectively evaluated. Patients with complete clinical and radiological data were included in the study. The demographic, clinical, and pathological characteristics of the patients were recorded. The timing of the initiation of IB therapy was categorized according to whether it was started at the first recurrence or at the second and subsequent recurrences. Factors associated with early-stage mortality (≤6 months) were determined using log-linear regression analysis, while independent prognostic factors affecting GSK were determined using the Cox proportional hazards regression model. Results: The mean age of patients was 53.01±12.78 years, and the mean follow-up period was 9.47 months. The mortality rate within the first 6 months was determined to be 44.9%. Early-stage mortality was found to be significantly associated with multilobular tumor localization (p=0.037) and initiation of IB therapy at ≥2nd stage (p=0.036). In the log-linear regression analysis, the probability of survival beyond 6 months was 5.05 times lower (RR=0.198, 95% CI: 0.054-0.735) in multilobular localization, while in those who started IB at ≥2nd node, it was 4.40 times lower (RR=0.227, 95% CI: 0.069-0.748). In the multivariate Cox regression analysis, starting IB at ≥2nd line (HR: 2.35, 95% CI: 1.09-5.07, p=0.029), the presence of IDH mutation (HR: 1.98, 95% CI: 1.09-3.58, p=0.025), and age (HR: 1.03, 95% CI: 1.01-1.05, p=0.015) were identified as independent prognostic factors for GSK. Conclusion: This retrospective cohort study based on real-world data demonstrates that the clinical benefit of the IB combination shows significant heterogeneity across patient subgroups. Multilobar tumor location and initiation of IB therapy in the late stages of recurrence are associated with early mortality and poorer survival. Our findings emphasize that IB therapy in recurrent brain tumors should be administered in a personalized manner, considering patient selection and treatment sequence, rather than as a routine approach.

  • Open Access

    The Pretreatment Glucose-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Ovarian Cancer

    by Ece Baydar, Yasemin Bakkal Temi, İlkay Çıtakkul, Devrim Çabuk, Umut Kefeli, Kazım Uygun

    Background/Objectives: This study aimed to assess the prognostic significance of the glucose-lymphocyte ratio (GLR) prior to therapy in individuals with epithelial ovarian cancer. Methods: This retrospective cohort study included 326 patients with epithelial ovarian cancer who were treated from 2011 to 2025. The GLR was computed utilizing pre-treatment fasting blood glucose levels and absolute lymphocyte numbers. The optimal GLR cutoff value was established by receiver operating characteristic (ROC) analysis. Overall survival (OS) and disease-free survival (DFS) were assessed utilizing Kaplan–Meier analysis and Cox regression models. Additional sensitivity analyses were performed excluding patients with diabetes mellitus and by testing the interaction between GLR and neoadjuvant chemotherapy. Results: The optimal GLR cutoff value was 3.42. Patients were classified into low-GLR (≤3.42; n = 190) and high-GLR (>3.42; n = 136) groups. Patients with high GLR levels (>3.42) had a median OS of 58 months, which was significantly shorter than the 151 months for patients with low GLR levels (≤3.42) (p < 0.001). They also had a median DFS of 17 months, which was significantly shorter than the 49 months for patients with low GLR levels (p < 0.001). Multivariable Cox regression analysis showed that a higher GLR is an independent prognostic factor related to shorter overall survival (HR: 1.561; 95% CI: 1.078–2.261; p = 0.018). Findings remained consistent after excluding patients with diabetes mellitus. The group with a high GLR had a greater rate of disease progression (55.1% vs. 29.5%, p < 0.001). Conclusions: The pre-treatment GLR may serve as a simple and readily available prognostic biomarker in epithelial ovarian cancer, potentially supporting basic risk stratification; however, external validation is required.

  • Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

    by Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu, Hayati Arvas, Harun Muglu, Ahmet Bilici, Mustafa Seyyar, Halil Goksel Guzel, Banu Ozturk, Ozge Yalıcı, et al.

    Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, has demonstrated efficacy in pivotal trials in both pretreated and treatment-naïve patients with ALK-positive non-small-cell lung cancer (NSCLC). However, real-world evidence from large multicenter cohorts remains limited. We conducted a retrospective multicenter study including 114 patients with advanced ALK-positive NSCLC treated with brigatinib across 28 centers in Turkey between May 2020 and December 2024. Objective response rate (ORR) was assessed by RECIST v1.1. Median progression-free survival (mPFS) and overall survival (mOS) were estimated by the Kaplan-Meier method, and prognostic factors were analyzed using Cox regression. The median age was 55 years. Brigatinib was administered as first-line therapy in 68.4% of cases. In the overall cohort, the mPFS and OS were 24.2 and 44.2 months. The ORR was 70.2%. In the first-line setting, the ORR was 79.5%, with an mPFS of 28.6 months and an mOS of 50.3 months. In contrast, those treated in the second-line or later setting had less-favorable outcomes, which independently correlated with worse OS in multivariate analysis. Patients with baseline brain metastases achieved favorable outcomes, with an mPFS of 26.2 months, an mOS of 46.3 months, and an ORR of 76.5%. Adverse events were reported in 83.3% of patients, most commonly gastrointestinal toxicities, creatine phosphokinase elevation, and liver enzyme abnormalities. This nationwide multicenter study offers comprehensive real-world evidence confirming the effectiveness and tolerability of brigatinib in ALK-positive NSCLC, with especially favorable outcomes in the first-line setting and in patients with brain metastases.

  • Real-World Validation of the KELIM Score for Predicting Chemosensitivity and Survival in Advanced Ovarian Cancer

    by Yasemin Bakkal Temi, İlKay Çitakkul, Ece Baydar, Sibel Balcı, Devrim Çabuk, Umut Kefeli, Kazım Uygun

    Aim: We evaluated the prognostic significance of the KELIM score, which is derived from CA-125 kinetics, in predicting survival outcomes among patients with advanced epithelial ovarian cancer in a real-world clinical context. Material and Methods: This retrospective study analyzed 238 patients with stage III-IV ovarian cancer treated between 2017-2024. KELIM scores, calculated from CA-125 kinetics during the first 100 treatment days, were categorized as high (favorable, >0.9) or low (unfavorable, ≤0.9) based on the ROC analysis. Survival outcomes were assessed using Kaplan-Meier and Cox regression analyses. Results: Patients with low KELIM scores had significantly shorter median overall survival (33 vs. 68 months, p < 0.001) and progression-free survival (11 vs. 18 months, p < 0.001) than those with high scores. Multivariate Cox regression analysis identified a low KELIM score as a significant predictor of poor overall survival (HR, 4.062; 95% CI, 2.711–6.087; p < 0.001). Additionally, disease progression was more frequent in patients with a low KELIM score (89.4%) than in those with a high KELIM score (69.9%, p = 0.001). Conclusion: The KELIM score serves as a practical and accessible prognostic biomarker for advanced ovarian cancer with the potential to inform early treatment decisions for patients who are unlikely to benefit from standard chemotherapy. Further prospective studies are warranted to validate their roles in personalized therapeutic strategies.


  • Open Access

    Real-World Evaluation of the HELPP Score and CALLY Index for Preoperative Prognostic Stratification in Resectable Pancreatic Ductal Adenocarcinoma

    by İlkay Çıtakkul, Umut Kefeli, Khatira Shukurova, Zehra Aytin, Yasemin Bakkal Temi, Ece Baydar, Kazım Uygun, Devrim Çabuk

    Background/Objectives: Preoperative prognostic assessment is essential for optimizing treatment strategies in pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate and compare the prognostic value of the Heidelberg Pancreatic Prognostic (HELPP) score and the C-reactive protein–albumin–lymphocyte (CALLY) index in patients with resectable PDAC. Methods: We retrospectively analyzed clinical and laboratory data of 109 patients with resectable PDAC who underwent curative-intent surgery and adjuvant therapy. Patients were stratified based on preoperative HELPP and CALLY scores. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis, while independent prognostic factors were determined through multivariate Cox regression. Results: Kaplan–Meier survival analyses demonstrated that a HELPP score > 3 and a low CALLY index (≤1.029) were significantly associated with worse OS and DFS (log-rank p < 0.05). In multivariate analysis, the HELPP score was identified as an independent predictor of survival, whereas the CALLY index, although associated with survival in univariate analysis, did not reach statistical significance. In ROC analysis, both models exhibited acceptable discrimination, with the HELPP score achieving superior AUC values in predicting 1-year OS compared to the CALLY index. Conclusions: The HELPP score demonstrated independent prognostic value in multivariate analysis and may serve as a robust preoperative tool in resectable PDAC. The CALLY index, although not independently significant in multivariate analysis, showed strong prognostic separation in Kaplan–Meier survival analyses and may still aid in preoperative risk stratification, particularly where access to comprehensive scoring systems is limited.


  • Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

    by Gökhan Şahin, Esmanur Kaplan Tüzün, Halil G. Güzel, Murad Guliyev, Ahmet K. Dişli, Melike Yazıcı, Oğuzhan Yıldız, Tuğçe K. Güneş, Süleyman Alkan, Emir G. Kahraman, et al.

    Non‐clear cell renal cell carcinoma (nccRCC) comprises a heterogeneous group of malignancies with limited prospective data and no established first‐line standard. We conducted a multicenter retrospective study across 29 centers in Turkey, including patients with advanced or metastatic nccRCC treated with first‐line cabozantinib or sunitinib between 2015 and 2025. Among 268 patients (sunitinib, n = 198; cabozantinib, n = 70), baseline characteristics were balanced. Cabozantinib was associated with significantly longer median progression‐free survival (PFS) compared to sunitinib (9.2 vs. 6.6 months; HR: 0.66; p = .027), while overall survival (OS) was similar (18.6 vs. 17.2 months; p = .566). Objective response rate (ORR) was higher with cabozantinib (38.6% vs. 26.3%; p = .052). Multivariate analyses identified ECOG performance status ≥2, IMDC risk category, sarcomatoid differentiation, and chromophobe histology as independent prognostic factors for OS. Predictors of PFS included IMDC risk, sarcomatoid features, nephrectomy status, and histologic subtype. These findings suggest that cabozantinib may offer improved disease control over sunitinib in this diverse patient population and provide valuable real‐world insights for therapeutic decision‐making in the absence of prospective randomized data.